{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:04:45Z","timestamp":1695729885817},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1007\/s00105-007-1284-2","type":"journal-article","created":{"date-parts":[[2007,1,19]],"date-time":"2007-01-19T09:41:43Z","timestamp":1169199703000},"page":"115-121","source":"Crossref","is-referenced-by-count":5,"title":["Rituximab (anti-CD20) zur Behandlung von bull\u00f6sen Autoimmundermatosen"],"prefix":"10.1007","volume":"58","author":[{"given":"M.","family":"Kasperkiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1284_CR1","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","volume":"26","author":"Ahmed","year":"2006","unstructured":"Ahmed AR, Spigelman Z, Cavacini LA (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globuline. N Engl J Med 26: 1772\u20131779","journal-title":"N Engl J Med"},{"key":"1284_CR2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.0022-202X.2004.23930.x","volume":"125","author":"Bystryn","year":"2005","unstructured":"Bystryn JC, Rudolph JL (2005) IVIG treatment of pemphigus: how it works and how to use it. J Invest Dermatol 125: 1093\u20131098","journal-title":"J Invest Dermatol"},{"key":"1284_CR3","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"1284_CR4","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580\u20132589","journal-title":"Arthritis Rheum"},{"key":"1284_CR5","first-page":"266","volume":"16","author":"Niedermeier","year":"2006","unstructured":"Niedermeier A, Worl P, Barth S et al. (2006) Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 16: 266\u2013270","journal-title":"Eur J Dermatol"},{"key":"1284_CR6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435\u2013445","journal-title":"Blood"},{"key":"1284_CR7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2230.2006.02151.x","volume":"31","author":"Schmidt","year":"2006","unstructured":"Schmidt E, Hunzelmann N, Zillikens D et al. (2006) Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 31: 503\u2013508","journal-title":"Clin Exp Dermatol"},{"key":"1284_CR8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1046\/j.1365-2133.2003.05302.x","volume":"148","author":"Schmidt","year":"2003","unstructured":"Schmidt E, Klinker E, Opitz A et al. (2003) Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148: 1222\u20131229","journal-title":"Br J Dermatol"},{"key":"1284_CR9","first-page":"132","volume":"126","author":"Shimanovich","year":"2006","unstructured":"Shimanovich I, Nitschke M, Rose C et al. (2006) Combined treatment of severe pemphigus with rituximab and protein A immunoadsorption. J Invest Dermatol 126: 132 (abstract)","journal-title":"J Invest Dermatol"},{"key":"1284_CR10","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","volume":"48","author":"Silverman","year":"2003","unstructured":"Silverman GJ, Weisman S (2003) Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48: 1484\u20131492","journal-title":"Arthritis Rheum"},{"key":"1284_CR11","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"Smith","year":"2003","unstructured":"Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanism of action and resistance. Oncogene 22: 7359\u20137368","journal-title":"Oncogene"},{"key":"1284_CR12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","volume":"15","author":"Tedder","year":"1994","unstructured":"Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15: 450\u2013454","journal-title":"Immunol Today"},{"key":"1284_CR13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.biopha.2004.04.006","volume":"58","author":"Virgolini","year":"2004","unstructured":"Virgolini L, Marzocchi V (2004) Rituximab in autoimmune diseases. Biomed Pharmacother 58: 299\u2013309","journal-title":"Biomed Pharmacother"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-007-1284-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-007-1284-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-007-1284-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T20:22:35Z","timestamp":1587327755000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-007-1284-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["1284"],"URL":"https:\/\/doi.org\/10.1007\/s00105-007-1284-2","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}